I have worked as a project manager in the oil and gas industry for the last 5 years. I have managed projects across the sector, working in downstream, midstream, and upstream oil. I have some exposure to CSG and tight gas surface facilities.
I have a B.Sc in Mechanical Engineering and have studied petroleum engineering, statistical programming, finance, and business.
Principal En-lightener - Purveyor of Darkness.
And Now - The Gift...
Stupid is as stupid does - Forrest Gump;
You can't fix stupid, no pill for it, it's fo'ever - Ron White ;
There are idiots, look around - Larry Summers ;
To avoid the pernicious global plague of stupidity, drink the Kool-Aid and become one of the innoculati. The Kool-Aid is available at [VIRUS REMOVED BY ECHELON UNDER ORDER OF PATRIOT ACT II ... transmission terminated]
Richard Zeits is an Oil & Gas industry analyst and consultant. His background includes fourteen years as Energy industry-focused investment banker, portfolio manager and senior investment analyst with bulge bracket firms in New York. Zeits Energy Analytics use elaborate proprietary analytics and data bases to provide in-depth industry research, market intelligence, and forecasting.
Contrarian - Independent Thinker.
I have little faith in our financial system. There is NO free market PERIOD. We are all pawns in the bankers game.
Basic rules I have learned over the years:
1) Follow the flow of money and the technical trends. I am primarily a technical trader.
2) Don't be greedy / buy when others are scared.
3) The news (fundamentals) for the most part is a waste of time for the small guy. The news is old by the time we get it. The news is priced in by the time I read it..
4) Sadly our financial system is grossly distorted by the FED.This leads to a different investment approach. Accept the market is corrupt (Not a free market).
Elon Musk is my hero. A true entrepreneur that made money doing something very difficult. Design rockets and electric cars.
I'm a CFA Charterholder and hold an MBA in Finance.
I spend a large amount of my free time analyzing and investing in energy companies of varying size. I'm currently covering oil and gas producers in the Permian Basin and the Eagle Ford. I try to provide quarterly coverage for several companies. I also look at oil and gas producers globally, in search of strong value plays. Anytime I find one, I write about it.
I will do my absolute best to provide quality research for you to consider in your investment decisions. However, I suggest you consult with your financial advisor prior to taking any action after reading an article, comment, private chat, or any other communication that I wrote. I urge you do your own research and draw your own conclusions prior to taking any action. My articles or comments are your starting point for your research. After you enter a trade, you are on your own to enter, exit, or take no action on the trade. I am not liable for actions you take after reading something that I wrote.
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 35 years executive experience including Abbott and JNJ and has been involved three successful start-ups. Before starting Raygent and other companies he was also a Technology Transfer Officer at UCLA. He has a B.S. from Penn State University and an MBA from Rutgers University.
His WEB site at www.raygent.com is currently focused in biopharmaceuticals, genomics and clinical diagnostics . Mr. Raynovich has extensive expertise in marketing and product development and provides business development consulting to early stage companies in biotechnology, diagnostics and imaging.
The Rayno Life Science Portfolio was published on www.raygent.com and other trade media.
Articles have been published on the following topics: Alzheimer Disease,Biomarkers, Genomics,Molecular Diagnostics, Oncology Drugs, Personalized Medicine, Targeted Therapy, Technology Trends, H1N1 and Government Policy on biotechnology.
The Life Science Portfolio is up over 80% over a 24 mo. period as of 5/30/14and among the life science portfolio winners are ABAX, ALXN, AMRI, BIIB, CBST, GPRO, ILMN, QDEL,REGN, SGEN, and VPHM.
We publish Profit Confidential daily for our Lombardi Financial customers because we believe many of those reporting today’s financial news simply don’t know what they are telling you! Reporters are trained to tell you the news—not what it can mean for you! What you read in the popular news services, be it the daily newspapers, on the internet or TV, is the news from a “reporter’s opinion.” And there’s the big difference.
I have a Bachelors Degree In Business Administration. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks.
I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha, Talk Markets, and CNA Finance. I run my own biotechnology website Biotechpicklist.com and in addition I post stock market news on my other website Wallstreetrain.com
How many times have you seen a trader on CNBC talking about a chart set up that should result in a profitable trade. As a fundamental analyst, this really irked me because chart patterns shouldn't dictate the direction of share prices. For years, I'd heard bad trades being suggested because the chart looked good. It became so bad that at one firm the technical analyst ended up with the nickname "Crayons".
One day I realized that the price chart is a picture that embeds all the fundamental information that the smartest analysts, portfolio managers and traders could gather. Large mutual funds spend millions of dollars researching and idea and the chart gives you a glimpse into what other smart people believe. I still don't believe that stocks move because of a chart but a chart pattern can be a signal to start doing work.
Now rather than simply looking for the companies that have the biggest market opportunity, I use fundamental set ups to add ideas to my watch list and wait chart patterns to signal when to buy.
In the series "What's Working". I highlight and discuss the fundamentals behind technically strong stocks. The chart may look good but why does it look good. Is the fundamental reason for the move sustainable? Is it too expensive to chase? The goal is to offer you new ideas with a fundamental understanding of why the stock is working; a short article to jump start for your own process.
Stephen Simpson, CFA, is a freelance financial writer and investor.
I have worked for both sell-side and buy-side firms (equities and fixed income), with the largest percentage of my working time spent in med-tech. At this point I am now effectively in a "working retirement".
I write because I find that the process helps me take better notes, be more disciplined about modeling, and come up with a more coherent investment view for my portfolio management needs. If I'm writing about a stock, it's generally because I'm interested in it as an investment prospect or I think there's an interesting story to tell.
I don't share my models, so please don't ask.
More of my writings can be found at my blog Kratisto Investing (kratistoinvesting.blogspot.com), or Twitter (@Kratisto_Invest).
The Infinity Group specializes in researching medium to large cap companies within the tech industries. Utilizing our technical background with our financial industry knowledge, we provide an insightful look at investment opportunities.
I'm an asset manager at Hebba Alternative Investments with a focus on real assets. In my articles I like to focus on events that affect the macro environment for assets (especially gold and silver), and also introduce readers to different metrics that I believe are under-utilized when assessing investments.
On a more personal note, I'm a firm believer that there can be honesty, morality, and integrity in finance (though its rare) and i'd like to believe that I stick to those principles. Thus I never "pump and dump" stocks, I always list the securities we own, and I take it very seriously when I recommend a company - I do not want to see any investors/readers lose money because of my recommendations.
I'm not always right with recommendations, but investors and readers can know that I always tell the truth (there is no deception) and I eat my own cooking as recommendations are either always owned OR the reason I dont own them is given (usually related to restrictions on stocks I can buy).
Advising people in financial matters is a serious issue and integrity is much more important than money to me, but I do believe both can co-exist. You live with money, but after your death you only have your morality and integrity and thus i've made my choice between the two. A bit philosophical for a bio, but I dont think there's a better way to give investors my background than that.
We offer investors a free weekly email list detailing gold, silver, and general economic markets which you can sign up for at: http://www.communitysynergy.com/subscribe/hebbainvestments_subscribe.html
I have a Bachelors Degree in Business Administration and have started up a website with the top 25 biotech stocks. I have been investing in biotech stocks for the last five years, and have done very well. My investing centers around being in long term in biotech stocks, because of the long term value potential. I like the risks in the biotech sector, along with the huge rewards.
Grant Zeng has over 10 years of professional experience in equity research and analysis. Grant joined Zacks Investment Research Inc. in March 2006, and currently is a senior equity analyst covering biotech/pharma industry. Before joining Zacks, Grant worked for TheStreet.com as a biotech analyst from 2005-2006. From Sept 2001 to December 2003, Grant worked for China Pacific Insurance Co. as an senior equity/fund analyst. Grant was a healthcare equity analyst with Young & Partners, LLC from Aug 2000 to September 2001. Grant had also teaching and researching experience in pharmaceutical science.
Grant Zeng obtained his MBA with a major in Finance in 2000 from McMaster University, Canada. He also holds a Master of Science in Biochemistry from the University of Western Ontario, Canada; Master of Pharmacology and Bachelor of Medicine from Second Military Medical University, China.
Grant Zeng is a Chartered Financial Analyst (CFA) charter holder.
I am an individual investor with over 15 years experience in the stock and options markets. I focus on the precious metals, energy, and tech sectors. I believe that there are always opportunities in any kind of market, and I actively look for strategies to take advantage of these opportunities. My long-term outlook is that stock and commodity prices will go higher, and bond prices will go lower. Some of the investing principles that I follow include (1) taking what the market gives you, (2) investing where you have a competitive advantage, (3) having a plan in case a stock goes up or down, and (4) investing only when the odds are in your favor.
I focus on the microcap space (market cap below $250 million) because it is one of the most inefficient and "alpha rich" areas of the global equity market, which provides the greatest opportunity to generate alpha through fundamental research.
I use a bottom up, investment decision making process. The ideal investment has an asymmetric risk/return profile with a limited downside (e.g. high net cash balance, strong cash flow) and significant upside (e.g. asset value extraction, overlooked business model transition).
Microcaps are particularly attractive to the following groups:
Activist investors. A small absolute investment (on a dollar basis) can be leveraged into a relatively large position (as a percentage of shares outstanding), which provides a greater ability to demand change.
Private equity firms. The persistent microcap discount can be “arbed away” via an LBO with the new owners accruing all of the gains for themselves. The small absolute size of many microcaps on an EV basis significantly expands the number of firms able to pursue this strategy.
This inefficiency exists for several reasons.
A lack of analyst coverage due to lower trading volume (less soft dollars from HF/MF), the global settlement that permanently severed the link between research/banking and the rise in electronic trading/decimalization. Moreover, none of these trends are likely to reverse for the foreseeable future (if ever).
A lack of institutional products given the natural capacity constraint for new/existing managers.
An inability to effectively implement a passive approach (e.g. ETFs, index funds) due to the lower liquidity and wider bid/ask spread. However, each of these obstacles can be overcome by using a combination of electronic trading tools (e.g. algos) and patience in building a positive size.
Inaccurate and persistent misconceptions about microcaps (e.g. they are riskier than larger cap stocks).
I currently trade for my personal account but would like to move into the investment management side of the industry.
I am an extreme contrarian investor, aquarium hobbyist and health-food guzzler. Let it be known that I intend to examine opinions, and see if they can be backed up with evidence. Also, I try to be as easy going as possible, but apologize in advance for any unholy rambling rants that occur while I write an article under the influence of coffee.
I realize that there is a lack of understanding regarding the basic tenants of economics. As such I hope to be able to explain concepts in an easily accessible manner that will allow people to figure out if policies are beneficial in the short run, long run, or not at all.
Feel free to check out my articles about layman economics on the Business Times http://www.btinvest.com.sg/blogs/filter/by_reporter?id=1621
Investment Banking (New York) - 1983-1986, 1988-1990
Banking / Investment Management - 1990 - 1996
Family Office Manager & Principal - 1996 to Present
Led a successful shareholder campaign in 2009 to oust Ken Lewis and 3 directors from board of Bank of America.
Mark McQueen is President & CEO of Wellington Financial LP, a privately-held corporate debt fund with offices in San Francisco, Santa Monica and Toronto. He has led Wellington's growth from its inception as a $7 million fund in 2000 to its current $600 million investment program ($200 million fund size). He was previously a Managing Director and Head of Technology Investment Banking of a leading independent investment bank, and before that part of a team that advised on over $25 billion in transactions as a member of the Mergers and Acquisitions group at a Canadian bank-owned investment dealer. Mark received credit training at a Canadian Chartered bank and was certified for commercial lending in 1995. He currently serves as the Chairman of the Toronto Port Authority, and several non-profit organizations. He is not licenced to give investment advice. All posts are Opinion Pieces and were copied by Seeking Alpha from their original publication site at www.wellingtonfund.com/blog.
Visit his site: Wellington Financial (http://www.wellingtonfund.com/) and blog (http://www.wellingtonfund.com/blog/index.php)
Chris (email@example.com) is an Hon B.Sc graduate (with distinction) in Science and Economics with over 15 years in investing experience. He holds a PMP (Project Management Professional) designation. TipRanks Top 100 Blogger of 2015 (also 2013, 2014). Seeks undervalued, unappreciated value stock ideas. Follows Warren Buffet's mantra: do not lose money. For a better mobile experience on Seeking Alpha click on the top right menu icon on most browsers and select "request desktop site".
Hi I'm Lior, an MA graduate in Economics. I have worked for several years in a variety of economic related positions, and in 2010 I started my own blog – Trading NRG, which is a news and analysis blog about gold, silver, natural gas and oil.